文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肉样瘤病中免疫抑制剂与肿瘤坏死因子抑制剂的比较结局与副作用:真实世界数据分析

Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis: A Real-World Data Analysis.
PubMed 文献 · Chest · 2025-10-10
一句话结论真实世界数据显示,肉样瘤病使用霉酚酸酯较甲氨蝶呤1年住院、重症监护、机械通气、死亡及感染风险更高,英夫利西单抗与阿达木单抗严重副作用相似。

该研究为回顾性分析,使用TriNetX研究网络2012至2023年82家医疗机构的去标识化病历,纳入接受特定免疫抑制剂或TNF抑制剂的肉样瘤病患者,采用倾向性评分匹配控制混杂。在13,814例接受免疫抑制剂的患者中,霉酚酸酯较甲氨蝶呤的住院(HR 2.74)、重症监护(HR 2.37)、机械通气(HR 4.04)、死亡(HR 2.16)及感染风险更高;硫唑嘌呤较甲氨蝶呤死亡、血液学毒性及感染风险增加。在3,964例接受TNF抑制剂的患者中,英夫利西单抗与阿达木单抗严重副作用总体相似,但英夫利西单抗贫血(HR 1.81)、血小板减少(HR 2.67)及肺炎(HR 1.47)风险略高,皮肤软组织感染风险较低(HR 0.39)。

要点

  • 肉样瘤病使用霉酚酸酯较甲氨蝶呤1年住院风险更高(HR 2.74;95%CI 2.11-3.56)。
  • 霉酚酸酯较甲氨蝶呤需重症监护(HR 2.37;95%CI 1.91-2.94)及机械通气(HR 4.04;95%CI 2.63-6.21)风险更高。
  • 霉酚酸酯较甲氨蝶呤死亡风险更高(HR 2.16;95%CI 1.70-2.75),感染风险亦更高。
  • 硫唑嘌呤较甲氨蝶呤死亡、血液学毒性及感染风险增加。
  • 英夫利西单抗与阿达木单抗严重副作用相似,英夫利西单抗贫血、血小板减少及肺炎风险略高,皮肤软组织感染风险较低。

适用人群与场景

  • 肉样瘤病患者,2012至2023年间在82家医疗机构接受特定免疫抑制剂或TNF抑制剂治疗。

研究设计与关键结果

  • 回顾性分析TriNetX研究网络82家医疗机构2012至2023年去标识化病历,采用倾向性评分匹配控制混杂。
  • 共13,814例接受免疫抑制剂的患者纳入分析。
  • 霉酚酸酯较甲氨蝶呤:住院HR 2.74(95%CI 2.11-3.56),重症监护HR 2.37(95%CI 1.91-2.94),机械通气HR 4.04(95%CI 2.63-6.21),死亡HR 2.16(95%CI 1.70-2.75),感染风险更高。
  • 硫唑嘌呤较甲氨蝶呤:死亡、血液学毒性及感染风险增加。
  • 3,964例接受TNF抑制剂的患者中,英夫利西单抗与阿达木单抗严重副作用相似。
  • 英夫利西单抗较阿达木单抗:贫血HR 1.81(95%CI 1.22-2.67),血小板减少HR 2.67(95%CI 1.75-4.07),肺炎HR 1.47(95%CI 1.02-2.10),皮肤软组织感染HR 0.39(95%CI 0.17-0.89)。

证据类型、等级与局限

  • 证据类型:回顾性真实世界数据分析,采用倾向性评分匹配。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与甲氨蝶呤相比,霉酚酸酯感染和骨髓抑制风险更高;英夫利西单抗与阿达木单抗严重副作用发生率相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sarcoidosis is a complex systemic granulomatous disease with varying clinical manifestations, and immunosuppressive agents and tumor necrosis factor (TNF) inhibitors have been used in severe and refractory cases. However, the comparison of the serious side effects of these treatments remains poorly understood.

RESEARCH QUESTION: In sarcoidosis, what is the 1-year risk of serious side effects among second-line agents (immunosuppressants) and TNF inhibitors?

STUDY DESIGN AND METHODS: A retrospective analysis of data from the TriNetX Research Network, which includes de-identified medical records of patients with sarcoidosis treated with specific immunosuppressive agents or TNF inhibitors between 2012 and 2023 across 82 health care organizations. Propensity score matching (PSM) was used to mitigate confounding effects.

RESULTS: A total of 13,814 patients receiving immunosuppressive agents were included. We found that patients who received mycophenolate mofetil (MMF) showed higher risks for inpatient hospitalization (hazard ratio [HR], 2.74; 95% CI, 2.11-3.56), critical care (HR, 2.37; 95% CI, 1.91-2.94), mechanical ventilation (HR, 4.04; 95% CI, 2.630-6.21), mortality (HR, 2.16; 95% CI, 1.70-2.75), and infections compared with those who received methotrexate. Azathioprine use showed increased risks for mortality, hematologic toxicity, and infections compared with methotrexate use. Among the 3,964 patients with sarcoidosis receiving TNF inhibitors, we found similar rare occurrence of serious side effects between infliximab and adalimumab, although a slightly higher risk of anemia (HR, 1.81; 95% CI, 1.22-2.67), thrombocytopenia (HR, 2.67; 95% CI, 1.75-4.07), and pneumonia (HR, 1.47; 95% CI, 1.02-2.10), but lower risk of skin soft tissue infection (HR, 0.39; 95% CI, 0.17-0.89) in the infliximab group.

INTERPRETATION: We used large real-world data with a PSM approach to demonstrate the heightened risk of infection and bone marrow suppression with MMF compared with the other immunosuppressants and a similar rate of serious side effects between infliximab and adalimumab.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Chao WC, Liao SY. Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis: A Real-World Data Analysis. Chest. 2025. PMID: 41077383. doi:10.1016/j.chest.2025.09.130

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。